Table 3 Mortalitya in people with polypharmacy (N = 1356) by cluster, ELSA 2018
| Â | Cluster 1 RAAS inhibitors | Cluster 2 Mental health drugs | Cluster 3 CNS drugs | Cluster 4 RAAS inhibitors + antithrombotics | Cluster 5 Antithrombotics |
|---|---|---|---|---|---|
(N = 194) % (N) | (N = 298) % (N) | (N = 387) % (N) | (N = 352) % (N) | (N = 125) % (N) | |
All-cause mortality | 15.5 (30) | 22.2 (66) | 12.9 (50) | 16.8 (59) | 24.0 (30) |
CVD mortality | 4.6 (9) | 10.4 (31) | 4.1 (16) | 8.5 (30) | 8.0 (10) |
Non-CVD mortality | 10.8 (21) | 11.7 (35) | 8.8 (34) | 8.2 (29) | 16.0 (20) |